Shape Changes Induced by N-Terminal Platination of Ubiquitin by Cisplatin

被引:49
作者
Williams, Jonathan P. [1 ]
Phillips, Hazel I. A. [1 ]
Campuzano, Iain [2 ]
Sadler, Peter J. [1 ]
机构
[1] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England
[2] Waters Corp, Manchester, Lancs, England
关键词
MOBILITY-MASS-SPECTROMETRY; ION MOBILITY; PROTEIN-BINDING; ELECTROSPRAY-IONIZATION; STRUCTURAL TRANSITIONS; ANTICANCER DRUGS; PLATINUM; SITES; COMPLEXES; PHARMACOKINETICS;
D O I
10.1016/j.jasms.2010.02.012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The three-dimensional conformation of a protein is an important property and plays a key role in its biological activity. We show here that ion mobility-mass spectrometry (IM-MS) can be used to detect conformational changes in the protein ubiquitin in the gas phase induced by reaction with the anticancer drug cisplatin. The primary adduct was ubiquitin-{Pt(NH3)(2)} under denaturing conditions. Up to three different conformations appear to be generated upon platination depending on the charge state. The collision cross-sections (Omega) for each conformation indicate that the conformations of the platinated protein are contracted in size compared with unmodified ubiquitin with generally smaller Omega values. Ion mobility-tandem MS allowed determination of the platinum binding site without a requirement for prior chromatographic separation. A rapid 30-min digestion of cisplatin-modified ubiquitin with trypsin allowed the platination site to be identified as the N-terminal methionine following low-energy collision-induced dissociation (CID) studies of the modified peptide. The data were generated using a Traveling-Wave based ion mobility-MS approach. Such cisplatin-induced shape changes may have a significant effect on its function in vivo. This work highlights the usefulness of the ion-mobility mass spectrometry technique for shedding new light on such protein interactions. (J Am Soc Mass Spectrom 2010, 21, 1097-1106) (C) 2010 Published by Elsevier Inc. on behalf of American Society for Mass Spectrometry
引用
收藏
页码:1097 / 1106
页数:10
相关论文
共 46 条
[1]   Donor atom preferences in complexes of platinum and palladium with amino acids and related molecules [J].
Appleton, TG .
COORDINATION CHEMISTRY REVIEWS, 1997, 166 :313-359
[2]  
Baker ES, 2004, PHYS CHEM CHEM PHYS, V6, P2786
[3]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[4]   Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c [J].
Casini, Angela ;
Gabbiani, Chiara ;
Mastrobuoni, Guido ;
Messori, Luigi ;
Moneti, Gloriano ;
Pieraccini, Giuseppe .
CHEMMEDCHEM, 2006, 1 (04) :413-417
[5]  
CLEMMER DE, ON LINE CROSS SECTIO
[6]   Identification of platination sites on human serum transferrin using 13C and 15N NMR spectroscopy [J].
Cox, MC ;
Barnham, KJ ;
Frenkiel, TA ;
Hoeschele, JD ;
Mason, AB ;
He, QY ;
Woodworth, RC ;
Sadler, PJ .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 1999, 4 (05) :621-631
[7]  
DECONTI RC, 1973, CANCER RES, V33, P1310
[8]  
Dhara S.C., 1970, INDIAN J CHEM, V8, P193
[9]  
Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI DOI 10.1002/9783906390420.CH4
[10]   A mass spectral study of the binding of the anticancer drug cisplatin to ubiquitin [J].
Gibson, D ;
Costello, CE .
EUROPEAN MASS SPECTROMETRY, 1999, 5 (06) :501-510